ClinicalTrials.gg
RecruitingNCT05569382TEMPO IIUpdated Mar 20, 2025

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

A Phase 4 interventional study of Verapamil and Bisoprolol in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Morten Steen Kvistholm Jensen. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Morten Steen Kvistholm Jensen · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark — 2 open to participants now, 3 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Denmark.

Planned enrollment
9th of 12
100 · median 213
Started
2022
with 2 others
Phase 4
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
Morten Steen Kvistholm Jensen

Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, this one is the 9th largest by planned enrollment, is one of 3 that started in 2022, is the only one in phase 4, and was the 10th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, or all of them as a file.
02

Study summary

Aim: to compare the treatment effects of Bisoprolol (beta 1 receptor specific beta blocker (BB)) and Verapamil (cardio-specific calcium channel blockers (CCB)) in patients with non-obstructive hypertrophic cardiomyopathy (HCM).

Background: Hypertrophic cardiomyopathy (HCM) is characterized by hypertrophy of the left ventricular wall and a hypercontracted state of the sarcomeres. This narrows the left ventricular cavity, but though the left ejection fraction is increased the stroke volume and the cardiac output cannot be fully compensated. The disease manifestations can be mild or develop into severe functional limitations and devastating complications at early age. Dyspnea, chest pain, palpitations and syncope are the most common symptoms, and patients are at risk of supraventricular and ventricular arrhythmias. Arrhythmias and sudden cardiac deaths may precede heart failure symptoms. Patients with symptomatic HCM are treated initially with beta blockers and calcium channel blockers. However, there is limited evidence supporting the effectiveness of this guideline-recommended treatment in HCM.

Methods: The study is a multicenter, double-blinded, randomized, placebo-controlled cross-over trial. Patients are randomized in to three 35-days treatment periods with Bisoprolol, Verapamil and Placebo. Each treatment period includes a 7-days up titration period, a 21-days target dose period and a 7-days down titration period. Between treatment periods 45 days treatment pause is allowed. End point will be evaluated at day 21 (- 4 days). Patients will be evaluated by cardiopulmonary exercise test, echocardiography, 7 day Holter-monitoring, biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ). A subgroup of patients will also be evaluated with cardiac magnetic resonance imaging.

Hypotheses: Three separate phases each with one primary effect parameters will be analyzed between treatment with Bisoprolol and Verapamil:

Phase 1: The maximal oxygen consumption (VO2 max) is different (ΔVO2 max ≥1 ml/kg/min) between treatments in non-obstructive HCM patients Phase 2: The left ventricular enddiastolic volume (LVvol) is different (ΔLVvol ≥3 ml) between treatments in non-obstructive HCM patients.

Phase 3: The incidence of non-sustained ventricular tachycardia (NSVT) is different (Hazard ratio ≥ 0.5) between treatments in non-obstructive HCM patients.

The trial will be performed and analyzed in three phases, and each phase may be unblinded and analyzed separately.

03

Conditions studied

  • Non-obstructive Hypertrophic Cardiomyopathy

Keywords

  • Hypertrophic cardiomyopathy
  • Bisoprolol
  • Verapamil
  • Beta Blocker
  • Calcium-channel Blocker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Maximal wall thickness ≥ 15 mm unrelated to hypertension, valve diseases or storage diseases. And one of the following:

    1. - functional class (NYHA) ≥ II
    2. A history of NYHA class ≥ II before treatment with BB or CCB
    3. Pro-BNP>300 ng/l/35>nmol/l or BNP >100ng/l/>29nmol/l
    4. Non-sustained VT (>120 min-1, ≥3 cycles) documented within the last 2 years of screening

Exclusion criteria

Exclusion Criteria:

  • \< 50%
  • LVOT gradient >30 mmHg at rest or during Valsalva maneuver after discontinuation of BB or CCB respectively
  • History of LVOT gradient >30 mmHg at rest, during exercise or during Valsalva maneuver.
  • Permanent atrial fibrillation
  • Permanent right ventricular pacing
  • Previous intolerance for Bisoprolol (BB) or Verapamil (CCB)
  • Known present obstructive coronary disease (previous percutaneous coronary intervention is accepted)
  • \< 40 ml/min
  • Fertile women (\<50 years) who are pregnant (Positive Plasma-HCG), breastfeeding or not using anticonception.
  • Significant liver failure
  • Severe valvular disease
  • Bradycardia (40bpm)
  • Hypotension (systolic \<100mmHg)
  • Other significant comorbidity or risks associated with discontinuation of BB or CCB after individual judgement by the investigators.
  • Unable to understand patient information intellectually or linguistically
  • Unable to perform exercise test.
  • Unable to speak and/or understand Danish.

Additional exclusion criteria for CMR sub study:

  • Implantable cardioverter defibrillator (any kind)
  • Pacemaker (any kind)
  • Metal implants like to affect image quality
  • Metal implants that poses a risk during CMR
  • Inability to cope with being in the scanner.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Verapamil

    Maximal tolerable dose (up to 360 mg per day)

    Drug: Verapamil

  • Active comparator
    Bisoprolol

    Maximal tolerable dose (up to 7,5 mg per day)

    Drug: Bisoprolol

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • 1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration

    Also known as: Isoptin Retard 240 MG, Verapamil Hydrochloride 240 MG

  • 1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration

    Also known as: Bisoprolol "Krka" 2.5 MG, Bisoprolol Fumarate 2.5 MG

  • DrugPlacebo

    1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration

    Also known as: Placebo oral capsule

06

What researchers measure

Primary outcomes

  1. Maximal oxygen consumption (VO2 max)

    Changes in VO2 max estimated during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  2. Left ventricular enddiastolic volume (LVvol)

    Changes in enddiastolic volume (LVvol) estimated during cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  3. Incidence of non-sustained ventricular tachycardia (NSVT

    Changes in NSVT estimated during ECG monitoring

    Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm

Secondary outcomes

  1. Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    Changes in KCCQ assessed by clinical evaluation

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  2. New York Heart Association (NYHA) functional classification

    Changes in NYHA class assessed by clinical evaluation

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  3. Canadian Cardiovascular Society (CCS) class

    Changes in CCS class assessed by clinical evaluation

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  4. Pro-BNP/BNP

    Changes in level of Pro-BNP/BNP in blood sample

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  5. High sensitive Troponin I/Troponin T

    Changes in level of high sensitive Troponin I/Troponin T in blood sample

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  6. Metabolic equivalent of task (METs)

    Changes in METs measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  7. Recovery time

    Changes in recovery time measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  8. VO2 max Anaerobic threshold

    Changes in VO2 max at anaerobic threshold measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  9. Percent predicted VO2 max

    Changes in percent predicted VO2 max measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  10. Ventilatory equivalent for carbon dioxide VE/VCO2

    Changes in VE/VCO2 measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  11. Echocardiographic left ventricular end-diastolic dimension

    Changes in left ventricular end-diastolic dimension measured during echocardiography

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  12. Echocardiographic global longitudinal strain (GLS) for LV function

    Changes in GLS measured during echocardiography

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  13. Echocardiographic left ventricular outflow tract time velocity intergral (LVOT VTI) for LV function

    Changes in LVOT VTI measured during echocardiography

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  14. Echocardiographic dimension of left atrial

    Changes in left atrial dimension measured during echocardiography

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  15. Episodes of atrial fibrillation (AFIB) on Holter monitoring

    Changes in episodes of AFIB measured during Holter monitoring

    Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm

  16. Number of ventricular ectopic beats on Holter monitoring

    Changes in number of ventricular ectopic beats measured during Holter monitoring

    Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm

  17. Left ventricular systolic function on Cardiac MRI

    Changes in left ventricular systolic function on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  18. Right ventricular dimensions on Cardiac MRI

    Changes in right ventricular dimensions on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  19. Right ventricular systolic function on Cardiac MRI

    Changes in right ventricular systolic function on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  20. Stroke volume (Aortic flow) on Cardiac MRI

    Changes in stroke volume (Aortic flow) on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  21. Coronary sinus flow on Cardiac MRI

    Changes in coronary sinus flow on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  22. Dimension of inferior and superior caval vein on Cardiac MRI

    Changes in dimension of inferior and superior caval vein on Cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  23. Dimension of left atrium on cardiac MRI

    Changes in dimension of left atrium on cardiac MRI

    Time frame: Changes will be evaluated at day 21 in each treatment arm

  24. Sex specific analyses of outcome measures

    Changes in outcome measures between male and female

    Time frame: Changes will be evaluated at day 21 in each treatment arm

07

Study locations

2 of 4 sites recruiting
  • Department of Cardiology, Aarhus University Hospital
    Aarhus N, 8200, Denmark
    Recruiting
    • Morten SK Jensen · Contactmorten.jensen@rm.dk · 004540145482
    • Louise Bjerregaard · Contactlbjer@clin.au.dk · 004540429833
    • Morten SK Jensen · Principal investigator
    • Steen H Poulsen · Sub investigator
    • Louise Bjerregaard · Sub investigator
  • Department of Cardiology, Odense University Hospital
    Odense, 5000, Denmark
    Recruiting
    • Lotte Saaby · Contact
  • Department of Cardiology, Zealand University Hospital
    Roskilde, 4000, Denmark
    Not yet recruiting
    • Martin Snoer · Contact
  • Department of Cardiology, Regional Hospital Viborg
    Viborg, 8800, Denmark
    Not yet recruiting
    • Erik S Nielsen · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Apr 2027, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 6, 2022
StartActual
Aug 10, 2022
Primary completionEst.
Apr 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05569382
Lead sponsor
Morten Steen Kvistholm Jensen
Collaborators
Viborg Regional Hospital, Zealand University Hospital, Odense University Hospital
Responsible party
Morten Steen Kvistholm Jensen (Consultant, PhD, Associated professor, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Oct 6, 2022
Start date
Aug 10, 2022
Primary completion
Apr 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Morten SK Jensen
Contact
morten.jensen@rm.dk
004540145482
Louise Bjerregaard
Contact
lbjer@clin.au.dk
004540429833

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Verapamil · Bisoprolol

Start the discussion